EXCLUSION CRITERIA - NEUROLOGIC:~Hemispheric stroke, hydrocephalus, subdural hematoma, or mass lesion on
neuroimaging study; epileptiform baseline EEG or known seizure disorder; head trauma with loss of consciousness
concurrent with onset of dementia; chronic CNS infection (positive MHA-TP or FTA-ABS acceptable if luetic brain
disease excluded by documented studies or treatment).~EXCLUSION CRITERIA - GENERAL MEDICAL:~Acute serious
infection, including hepatitis; hypothyroidism (TSH greater than 6.0 microunits/mL); folic acid deficiency
(less than 0.9 ng/mL); vitamin B12 deficiency (less than 160 pg/mL) within one year prior to enrollment; severe
renal insufficiency (creatinine clearance less than 25 mL/min, BUN greater than 40 mg/dL, or serum creatinine
greater than 2.0 mg/dL); hepatic insufficiency (SGPT or SGOT greater than 3 x upper limit of normal, or total
bilirubin greater than 2.0 mg/dL). Due to the serious adverse event transient agranulocytosis report in another
study of CX516, patients will neutropenia or low normal white blood cell counts (greater than or equal to 3.5
K/microliter) will be excluded from this study.~PSYCHIATRIC:~Depression if present during screening. Depression
will be diagnosed clinically and with depression rating scale(s), such as Hamilton Depression Rating Scale, if
needed.~PREVIOUS AND CONCOMITANT MEDICATIONS:~Administration of tacrine, donepezil, rivastigmine, galantamine,
anti-depressants are prohibited within thirty days prior to enrollment.~OTHER CONDITIONS:~Any hepatic,
cardiovascular, gastrointestinal, or hematological illness which could interfere with drug absorption,
distribution, metabolism, or excretion; known hypersensitivity to CX516 or its vehicle; inability to swallow
tablets or to comply with medication schedule; no significant care giver; uncorrectable loss of hearing or
eyesight that precludes psychometric testing; inability to comprehend instructions or to respond to test items.
